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Epinephrine in the Heart
Uptake and Release, but No Facilitation of Norepinephrine Release
Thomas W. Lameris, MD, PhD; Sandra de Zeeuw, PhD; Dirk J. Duncker, MD, PhD; Wouter Tietge, MSc;
Gooitzen Alberts, BSc; Frans Boomsma, PhD; Pieter D. Verdouw, PhD; Anton H. van den Meiracker, MD, PhD
Background—Several studies have suggested that epinephrine augments the release of norepinephrine from sympathetic
nerve terminals through stimulation of presynaptic receptors, but evidence pertaining to this mechanism in the heart is
scarce and conflicting. Using the microdialysis technique in the porcine heart, we investigated whether epinephrine,
taken up by and released from cardiac sympathetic nerves, can increase norepinephrine concentrations in myocardial
interstitial fluid (NEMIF) under basal conditions and during sympathetic activation.
Methods and Results—During intracoronary epinephrine infusion of 10, 50, and 100 ng/kg per minute under basal
conditions, large increments in interstitial (from 0.310.05 up to 14030 nmol/L) and coronary venous (from
0.160.08 up to 22839 nmol/L) epinephrine concentrations were found, but NEMIF did not change. Left stellate
ganglion stimulation increased NEMIF from 3.40.5 to 8.21.5 nmol/L, but again, this increase was not enhanced by
concomitant intracoronary epinephrine infusion. Intracoronary infusion of tyramine resulted in a negligible increase in
epinephrine concentration in myocardial interstitial fluid (EPIMIF), whereas 30 minutes after infusion of epinephrine an
increase of 9.5 nmol/L in EPIMIF was observed, indicating that epinephrine is taken up by and released from cardiac
sympathetic neurons. Although 68% to 78% of infused epinephrine was extracted over the heart, the ratio of interstitial
to arterial epinephrine concentrations was only 20%, increasing to 29% with neuronal reuptake inhibition.
Conclusions—Our findings demonstrate epinephrine release from cardiac sympathetic neurons, but they do not provide
evidence that epinephrine augments cardiac sympathoneural norepinephrine release under basal conditions or during
sympathetic activation. (Circulation. 2002;106:860-865.)
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Several in vitro as well as in vivo studies have suggestedthat epinephrine (EPI) enhances sympathoneural norepi-
nephrine (NE) release through stimulation of presynaptic
2-adrenoceptors located at the sympathetic nerve termi-
nals.1–5 This mechanism would be particularly important in
the heart because adrenomedullary activation in conditions
such as hypertension and heart failure could contribute to the
deterioration of cardiac function through chronically increas-
ing sympathoneural NE release by presynaptic facilitation.
Indeed, studies have shown that cardiac EPI is released into
the coronary circulation of the heart in conditions such as
hypertension and heart failure but also during exercise, at rest
with advanced age, and in patients with panic disorders.1,6,7
Furthermore, we have recently shown that prolonged myo-
cardial ischemia is associated with a progressive increase of
EPI concentrations in the myocardial interstitial fluid
(EPIMIF).8 Evidence that such an increased cardiac EPI con-
centration leads to an increase in cardiac NE by presynaptic
facilitation is, however, scarce and conflicting.1,5,9 In the
present study we have tested the hypothesis that locally
administered and coreleased EPI modulates interstitial NE
(NEMIF) concentrations under basal conditions and during
sympathetic activation induced by electrical stimulation of
the left stellate ganglion. At the same time we investigated the
extent to which EPI is taken up by and released from cardiac
sympathetic nerves and the source of cardiac EPI, because it
is still unclear whether EPI is released from sympathetic
nerve terminals after it has been taken up from the circulation
or whether it is released from extraneuronal stores.10,11
For this purpose, we measured interstitial EPI and NE
concentrations in the intact porcine heart by using the
microdialysis technique. The porcine heart is especially
suitable as a model for studying the cardiac sympathetic
nervous system, as the distribution of 1/2 adrenoceptors
(80%/20%)12 and the prevailing parasympathetic control of
cardiac function are very much akin to the human heart.
Increases in locally released EPI were obtained by loading the
heart with EPI by means of intracoronary EPI infusions. The
source of cardiac EPI was investigated through the effect of
intracoronary tyramine infusions on interstitial EPI concen-
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trations before and after loading the heart with EPI. Because
tyramine only displaces catecholamines from their storage
vesicles in the sympathetic nerve terminals after it has been
taken up by the neuronal reuptake (U1) mechanism,13,14
catecholamines released by tyramine are exclusively from
neuronal origin. Because 80% of neuronally released NE is
taken up by sympathetic nerves of the porcine heart through
the U1 mechanism,13 the U1 inhibitor desipramine was added
to the perfusate of one of the microdialysis probes to provide
local U1 blockade. In addition, we also accounted for a
possible inhibition of NE release through stimulation of
presynaptic  2-adrenoceptors by adding the nonselective
-adrenoceptor antagonist phentolamine to the perfusate of
another probe in combination with desipramine.
Methods
Animal Procedures
All experiments were performed in accordance with the “Guiding
Principles for Research Involving Animals and Human Beings” as
approved by the Council of the American Physiological Society and
under the regulations of the Animal Care Committee of the Erasmus
University Rotterdam.
Crossbred Landrace x Yorkshire pigs of either sex (30 to 35 kg,
n19; Oude Tonge, the Netherlands) were used. Treatment, surgical
procedure, and positioning of catheters and flow probes have been
described previously.8,13 In animals subjected to sympathetic stimu-
lation, the left stellate ganglion was dissected, and an electrode was
inserted into the ganglion as described previously by Gootman et al15
and connected to a nerve stimulator (Grass S9; pulses of 12 V, 10 Hz
and 5 ms).
Microdialysis probes were implanted in left ventricular (LV)
myocardium: one in the region perfused by the left circumflex
coronary artery (LCx) and three in the area perfused by the left
anterior descending coronary artery (LAD). One of the LAD probes
was coperfused with desipramine (DMI) (Sigma, 100 mol/L),14 and
one LAD probe was coperfused with DMI and the nonselective
-adrenoceptor blocking agent phentolamine (PHA) (Department of
Pharmacy, University Hospital Dijkzigt, Rotterdam; 100 mol/L).
The microdialysis technique, probe characteristics, probe recovery,
handling, and analysis of the microdialysis and plasma samples and
its sensitivity have been described previously.13,16
Experimental Protocol
After a 120-minute stabilization period, baseline measurements were
obtained over a 30-minute period. Probes were perfused with
Ringer’s solution (Baxter) at a flow of 2 L/min; dialysate was
collected at 10-minute intervals, in which blood was collected from
the central aorta (Ao) and the anterior interventricular coronary vein
(CV), which drains the LAD perfusion territory. In 9 animals,
intracoronary EPI was administered at infusion rates of 10, 50, and
100 ng/kg per minute, each for 30 minutes. Tyramine was infused
(26.7 g/kg per minute) for 30 minutes into the LAD 30 minutes
after discontinuation of the EPI infusions. To prevent possible
interference of tyramine infusions with subsequent EPI infusions, the
effect of tyramine infusion under basal conditions was studied in 4
separate animals. Finally, in 6 animals the left stellate ganglion was
stimulated electrically before and during concomitant infusion of 50
ng/kg per minute EPI.
Data Analysis and Calculations
Dialysate EPI and NE concentrations were corrected for probe
recovery to yield EPIMIF and NEMIF.8,13 Lower limits of detection
were 0.2 nmol/L in dialysate and 0.02 nmol/L in plasma.16 Baseline
values were determined by averaging the three measurements over
the 30-minute period before intervention. EPI plasma concentrations
in the LAD (EPICA) were calculated from EPI infusion rate, coronary
plasma flow, and EPIAo.
In addition, cardiac extraction of EPI, the ratio of the absolute
changes of interstitial to the absolute changes of arterial EPI
concentrations MIF/CA during EPI infusion, the percentage of
EPI that can be recovered from the MIF and that is taken up by U1,
spillover, uptake of released EPI from the interstitium, neuronal
release rate, and efficiency of total uptake of EPI were calculated.8,13
Statistical Analysis
All data are expressed as meanSEM. For statistical analysis, 2-way
ANOVA, 1-way ANOVA for repeated measures with Dunnett’s
multiple comparison test as post hoc test, Student’s t test, and linear
regression analysis were used as appropriate.
Results
Effect of Intracoronary EPI Infusions on NE and
EPI Concentrations
The intracoronary EPI infusions caused dose-dependent in-
creases in LV dP/dtmax (130%), heart rate (15%), and cardiac
output (20%), whereas mean arterial pressure (15%), sys-
temic vascular resistance (30%), and LV end-diastolic
pressure (20%) decreased (Table 1). In contrast, LAD flow
increased about 45%, independent of the infused dose.
Intracoronary infusion of EPI caused dose-dependent in-
creases in EPICV from 0.160.08 nmol/L at baseline up to
22839 nmol/L during infusion of 100 ng/kg per minute and
EPIMIF, LAD from 0.310.05 nmol/L up to 14030 nmol/L
(Figure 1). U1 inhibition did not affect EPIMIF, LAD at baseline
TABLE 1. Cardiovascular Function During Intracoronary Epinephrine Infusion
Baseline
Intracoronary Infusion of Epinephrine, ng/kg per minute
10 50 100
Mean arterial pressure, mm Hg 894 854 774* 763*
Cardiac output, L/min 2.60.2 2.60.2 2.80.2 3.10.3*
Heart rate, bpm 1257 1306 1376* 1447*
Systemic vascular resistance, mm Hg min1  L 374 323* 293* 262*
Stroke volume, mL 213 222 203 275
LV dP/dtmax, mm Hg/s 1604136 2483191* 3068222* 3716186*
LV end-diastolic pressure, mm Hg 72 62 62* 62*
LAD flow, mL/min 294 414* 414* 434*
Values are meanSEM (n9).
*P0.05 vs baseline.
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and the lowest EPI infusion rate but caused an increase in
EPIMIF, LAD to similar values as EPICV at the two higher
infusion rates. Although the cardiac EPI extraction was 68%
to 78%, there was a marked gradient between interstitial and
circulatory concentrations. During the intracoronary EPI
infusions, the MIF/CA ratio for EPI (Table 2) was
274%, 193%, and 213% in the absence of U1 blockade
and 293% in the presence of U1 blockade, irrespective of
the EPI infusion rate. Despite the large increments in circu-
latory and interstitial EPI concentrations, the pharmacokinetic
parameters for EPI as spillover, rate of uptake, rate of
neuronal release, and efficiency of uptake remained un-
changed (Table 2). Notwithstanding the aforementioned large
increments in EPICV and EPIMIF, LAD, NEMIF, LAD, NECV, and NEAo
did not change (Figure 2).
Intracoronary EPI Infusion and NE Release
During Sympathetic Activation
Left stellate ganglion stimulation caused increases in MAP
(21%), LAD flow (36%), and in particular LV dP/dtmax
(184%, Table 3 and Figure 3) and caused a rise in NEMIF,
particularly in the presence of U1 and -adrenoceptor block-
ade, where NEMIF, LAD increased from 3.40.5 to 8.21.5
nmol/L (Figure 3). Although intracoronary infusion of EPI
decreased MAP (25%) and systemic vascular resistance
(27%) and increased HR (22%), LV dP/dtmax (93%), and
LAD flow (32%), it did not alter the hemodynamic responses
to stimulation. Similarly, concomitant EPI infusion did not
enhance the NE release on stimulation of the left stellate
ganglion (from 2.60.3 to 6.91.5 nmol/L, Figure 3). In
addition, stimulation did not increase EPIMIF, LAD (588 versus
585 nmol/L), whereas EPICV even decreased (20116
versus 1586 nmol/L, P0.05).
Intracoronary EPI Infusion and
Tyramine-Induced EPI and NE Release
Intracoronary infusion of tyramine caused increases in mean
arterial pressure (20%), heart rate (20%), LV dP/dtmax (190%),
LAD flow (40%), and NEMIF, LAD (12.82.9 nmol/L, P0.05).
The small increase in heart rate compared with large increase
in LV dP/dtmax during intracoronary infusion of tyramine can
Figure 1. Effect of intracoronary epinephrine infusions on coro-
nary venous and interstitial epinephrine concentrations. Data are
shown for EPIMIF, LAD (white), EPIMIF, LADDMI (light gray), EPICV
(dark gray), and EPICA (black bars). Data are meanSEM, n9.
TABLE 2. Spillover, Uptake, and Release of Epinephrine Compared With Norepinephrine
Epinephrine, ng/kg per minute Norepinephrine, ng/kg per minute
10 50 100 110 330
MIF/A, % 274 193 213 101 111
MIFDMI/A, % 294 293* 313* 213* 365*†
Fx U1, % 175 376† 337† 517 675
Extraction, % 783 745 685† 794 693
SO, pmol/min 2.41.3 2.81.4 3.72.2 356 395
Ur, pmol/min 4610 5114 369 19433 20451
Rr, pmol/min 4911 5414 4010 22937 24353
EffU, % 953 962 943 842 792
Values are meanSEM. Epinephrine values are derived from data during intracoronary infusions of epinephrine in
the present study. Norepinephrine values are derived from historic data during systemic intravenous infusions of
norepinephrine.8
MIF/CA indicates the ratio of absolute changes of interstitial to absolute changes of arterial concentrations; Fx
U1, percentage recovered from myocardial interstitial fluid that is taken up by Uptake 1; SO, spillover; Ur, uptake of
released (nor)epinephrine from the interstitium; Rr, neuronal release rate; and EffU, efficiency of total uptake.
*P0.05 vs lowest dose.
†P0.05 vs without DMI.
Figure 2. Effect of intracoronary infusion of epinephrine (ng/kg
per minute) on basal cardiac sympathetic tone. Data are shown
for NEMIF, LAD (●), NEMIF, LADDMI (), NEMIF, LADDMIPHA (‘),
NE
MIF, LCX
(x), NEAo (solid bars), and NECV (hatched bars). Data are
meanSEM, n9.
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be explained by the poor perfusion of the sinus node with
tyramine by using this particular route of administration.
These responses were not affected by a preceding intracoro-
nary EPI infusion (Figure 4, Table 4). In contrast to the
increase in NEMIF, LAD, the change in EPIMIF, LAD during
tyramine infusion was negligible before but increased mark-
edly after intracoronary infusion of EPI (9.53.0 nmol/L,
P0.05). This was also reflected by the tyramine-induced
increase in EPICV from 0.090.01 nmol/L before to 8.12.7
nmol/L after EPI infusion (P0.05).
Discussion
Effect of Intracoronary EPI on NE Release
Although under basal conditions intracoronary EPI infusions
caused a 450-fold increase in interstitial and a 1400-fold
increase in coronary vein EPI concentration, we did not detect
any changes in interstitial or coronary vein NE concentra-
tions. Even under U1 inhibition and -adrenoceptor blockade
to prevent, respectively, rapid clearance and presynaptic
2-adrenoceptor–mediated inhibition of NE release by EPI or
NE itself, interstitial NE concentration did not increase during
intracoronary infusion of EPI.
It could be argued that in anesthetized animals, facilitation
of NE release by EPI is difficult to demonstrate because of the
low basal NE concentrations as compared with awake
swine.13,17 Hence, we investigated the effects of EPI on NE
release during sympathetic activation induced by electrical
stimulation of the left stellate ganglion. Left stellate ganglion
stimulation resulted in a marked increase in LV dP/dtmax,
LAD flow, and mean arterial pressure, but these responses
were not enhanced by an intracoronary infusion of EPI (Table
2 and Figure 3). During stimulation of the left stellate
ganglion, interstitial NE concentration increased up to 5-fold.
The absolute increase in NEMIF, LAD was most pronounced in
the presence of U1 and -adrenoceptor blockade, underscor-
ing the importance of the 2-adrenoceptor–mediated feedback
mechanism that inhibits neuronal NE release. Similar to the
hemodynamic responses, concomitant infusion of EPI did not
augment the response of NE to left stellate ganglion stimu-
lation, nor in the presence of U1 inhibition and
-adrenoceptor blockade (Figure 3).
TABLE 3. Cardiovascular Function During Stellate Ganglion
Stimulation Before () and During () Intracoronary Infusion
of Epinephrine
Baseline
Left Stellate
Ganglion
Stimulation
Mean arterial pressure, mm Hg
 873 1055*
 6711† 848*†
Cardiac output, L/min
 2.60.2 2.70.3
 2.80.5 3.20.5
Heart rate, bpm
 1086 1157
 1324† 1375†
Systemic vascular resistance,
mm Hg  min1  L
 343 414
 252† 283†
Stroke volume, mL
 251 241
 224 244
LV dP/dtmax, mm Hg/s
 148536 4220374*
 2864507† 5596980*†
LV end-diastolic pressure, mm Hg
 122 102
 83 73
LAD flow, mL/min
 285 385*
 373† 428
Values are meanSEM (n6). Epinephrine was given in an intracoronary
infusion of 50 ng/kg per minute.
*P0.05 vs baseline.
†P0.05 vs before intracoronary infusion of epinephrine.
Figure 3. Effect of intracoronary epinephrine
infusion on LV dP/dtmax (left) and NEMIF, LAD
DMIPHA (right) during left stellate ganglion
stimulation (LSG). EPI indicates intracoronary
infusion of epinephrine (50 ng/kg per minute).
Data are meanSEM, n6. *P0.05;
**P0.01; ***P0.001.
Figure 4. Effect of intracoronary tyramine infusion on concentra-
tions of NE and EPI in MIF before and after intracoronary infu-
sion of epinephrine. Data are meanSEM, n9.
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Our results are corroborated by studies that also failed to
demonstrate enhanced NE release by EPI in other tissues18–20
and in particular by the findings of Thompson et al,9 who
demonstrated that EPI did not increase NE spillover in the
human heart. However, they are at odds with studies showing
augmentation of pressor responses,2,4 increased plasma NE
concentrations,21 and increased forearm NE spillover in
humans,3,22 and in particular with two studies (also about the
heart) that reported increased NE outflow in rat atria5 and in
the human heart.1 The reason for the discrepancy between our
findings and those from the study by Majewski et al5 is
unclear but may be related to differences in species (espe-
cially because cardiac function in the rat is under predomi-
nant sympathetic control unlike that in pigs and humans) and
tissue (atria versus ventricle) studied. The other study by
Rumantir et al1 did not investigate the direct effect of EPI on
cardiac NE but only provided circumstantial evidence for the
epinephrine hypothesis through demonstration of a signifi-
cant correlation between the respective cardiac spillovers of
NE and EPI in hypertensive patients. The latter can also be
interpreted as evidence that NE and EPI are coreleased from
sympathetic neurons.
With the low-dose infusion of EPI, EPIMIF concentration
increased 20-fold. This concentration probably is higher
than EPIMIF concentrations occurring during congestive heart
failure. Nevertheless, we think that this EPIMIF concentration
is still in the relevant range as in a previous study in which we
showed that EPIMIF concentration rose to similar values
during severe ischemia.8
It might be argued that in the present study, facilitation of
NE release by EPI was obscured by either increased clearance
or sympathoinhibition. Indeed, LAD flow increased by 45%
during the lowest intracoronary EPI infusion, which might
explain the decrease in NEMIF, LAD observed in the presence of
2-adrenoceptor blockade and U1 inhibition (Figure 2). How-
ever, there were no further changes in LAD flow and NEMIF, LAD
when EPI infusion rate was further increased 5- to 10-fold
(Table 1 and Figure 2). In addition, the absence of an increase in
NEMIF, LAD during intracoronary infusion of EPI under U1 inhi-
bition and -adrenoceptor blockade indicates that the potentially
facilitating effect of EPI on NE release was not masked by rapid
clearance by U1 and local sympathoneural inhibition. Finally, it
could be argued that central sympathoinhibition during the
intracoronary infusion of EPI influenced our results. This is
unlikely, however, because the decrease in blood pressure that
occurred during EPI infusion would promote an increase rather
than a decrease in sympathetic outflow, although the absence of
an increase in sympathetic activity probably occurred because of
the pentobarbital anesthesia.23
EPI in the Heart: Release and Uptake
Under basal conditions, the tyramine-induced EPI release
could not be demonstrated, which is in agreement with earlier
results in the intact rabbit heart24 and probably reflects the
low intraneuronal EPI content (1% to 2% of cardiac NE
concentrations).25 After loading the heart with EPI by means
of an intracoronary EPI infusion, tyramine caused substantial
increases in EPIMIF and EPICV, which were comparable to the
increases in NEMIF and NECV. These findings unequivocally
demonstrate that in the porcine heart, EPI can be taken up
from the circulation by and released from the sympathetic
nerve terminals.
We found an EPI extraction of70% for the porcine heart.
Other experimental and human studies have reported that the
extraction of arterially delivered EPI by the myocardium
during a single pass is 50%. In all cases, however, the
cardiac extraction of EPI is considerably lower than the
cardiac extraction of NE (70% to 85%).1,6,13,26–28 Because U1
is the major determinant of the cardiac clearance of catechol-
amines and the affinity of EPI for the U1 mechanism is lower
than that of NE,27 it is likely that the difference in extraction
originates from this difference in affinity for U1. This is also
substantiated by the effect of U1 inhibition on MIF/CA.
Thus, depending on the infusion rate, only 17% to 37% of
infused EPI appears to be cleared by U1, whereas we have
previously shown that in the porcine heart U1 clears 51% to
67% of arterially delivered NE.13 The considerably higher
EPI extraction over the porcine heart compared with the
human heart, despite the relatively low clearance of EPI by
TABLE 4. Cardiovascular Function During Intracoronary
Infusion of Tyramine Before () and After () Intracoronary
Infusion of Epinephrine
Baseline Tyramine
Mean arterial pressure, mm Hg
 901 1094*
 783† 974*†
Cardiac output, L/min
 2.70.3 3.20.4*
 2.50.2 3.20.1*
Heart rate, bpm
 1287 1529*
 1288 1439*
Systemic vascular resistance,
mm Hg  min1  L
 364 374
 323 302†
Stroke volume, mL
 222 212
 202 242
LV dP/dtmax, mm Hg/s
 168389 4819433*
 1558213 4106333*†
LV end diastolic pressure, mm Hg
 61 63
 71 72
LAD flow, mL/min
 242 343*
 243 334*
Values are meanSEM (n9). Epinephrine was given in 3 consecutive
intracoronary infusions, each for 20 minutes (10, 50, and 100 ng/kg per
minute). The intracoronary infusion of tyramine was started 30 minutes after
the epinephrine infusions were discontinued.
*P0.05 vs baseline.
†P0.05 vs before intracoronary infusion of epinephrine.
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U1, suggests the presence of a more active extraneuronal
clearance mechanism for EPI in the porcine heart, as was also
reported for NE.13 As the resultant of release and uptake, the
modest EPI spillover rate of 3.0 pmol/min is in close
agreement with that estimated for the human heart and is10
times lower than the spillover rate of NE.1,7,27,28
In summary, although the present study shows that EPI is
taken up by and released from cardiac sympathetic nerves,
our findings in the porcine heart do not support the concept
that myocardial NE release is facilitated by EPI either under
basal conditions or during activation of cardiac sympathetic
tone induced by left stellate ganglion stimulation. Hence, we
hypothesize that the uptake of EPI by the heart is principally
a mechanism for rapid clearance of circulatory EPI and that
the small amount of locally released cardiac EPI does not
affect cardiac function.
Acknowledgments
This study was supported in part by a grant from the Netherlands
Heart Foundation (99.151). Dr Duncker is an Established Investiga-
tor (2000D038) of the Netherlands Heart Foundation.
References
1. Rumantir MS, Jennings GL, Lambert GW, et al. The ‘adrenaline
hypothesis’ of hypertension revisited: evidence for adrenaline release
from the heart of patients with essential hypertension. J Hypertens.
2000;18:717–723.
2. Blankestijn PJ, Man in ‘t Veld AJ, Tulen J, et al. Support for adrenaline-
hypertension hypothesis: 18 hour pressor effect after 6 hours adrenaline
infusion. Lancet. 1988;2:1386–1389.
3. Chang PC, Grossman E, Kopin IJ, et al. On the existence of functional
beta-adrenoceptors on vascular sympathetic nerve endings in the human
forearm. J Hypertens. 1994;12:681–690.
4. Floras JS, Aylward PE, Victor RG, et al. Epinephrine facilitates neu-
rogenic vasoconstriction in humans. J Clin Invest. 1988;81:1265–1274.
5. Majewski H, Rand MJ, Tung LH. Activation of prejunctional beta-
adrenoceptors in rat atria by adrenaline applied exogenously or released
as a co-transmitter. Br J Pharmacol. 1981;73:669–679.
6. Kaye DM, Lefkovits J, Cox H, et al. Regional epinephrine kinetics in
human heart failure: evidence for extra-adrenal, nonneural release. Am J
Physiol. 1995;269:H182–H188.
7. Esler M, Kaye D, Thompson J, et al. Effects of aging on epinephrine
secretion and regional release of epinephrine from the human heart. J Clin
Endocrinol Metab. 1995;80:435–442.
8. Lameris TW, de Zeeuw S, Alberts G, et al. Time course and mechanism
of myocardial catecholamine release during transient ischemia in vivo.
Circulation. 2000;101:2645–2650.
9. Thompson JM, Wallin BG, Lambert GW, et al. Human muscle sympa-
thetic activity and cardiac catecholamine spillover: no support for aug-
mented sympathetic noradrenaline release by adrenaline co-transmission.
Clin Sci (Colch). 1998;94:383–393.
10. Huang MH, Friend DS, Sunday ME, et al. An intrinsic adrenergic system
in mammalian heart. J Clin Invest. 1996;98:1298–1303.
11. Kennedy B, Ziegler MG. Cardiac epinephrine synthesis: regulation by a
glucocorticoid. Circulation. 1991;84:891–895.
12. Scholz J, Steinfath M, Roewer N, et al. Biochemical changes in malignant
hyperthermia susceptible swine: cyclic AMP, inositol phosphates, alpha
1, beta 1-and beta 2-adrenoceptors in skeletal and cardiac muscle. Acta
Anaesthesiol Scand. 1993;37:575–583.
13. Lameris TW, van den Meiracker AH, Boomsma F, et al. Catecholamine
handling in the porcine heart: a microdialysis approach. Am J Physiol.
1999;277:H1562–H1569.
14. Yamazaki T, Akiyama T, Kitagawa H, et al. A new, concise dialysis
approach to assessment of cardiac sympathetic nerve terminal abnor-
malities. Am J Physiol. 1997;272:H1182–H1187.
15. Gootman PM, Gandhi MR, Coren CV, et al. Cardiac responses elicited by
stimulation of loci within stellate ganglia of developing swine. J Auton
Nerv Syst. 1992;38:191–200.
16. Alberts G, Lameris T, van den Meiracker AH, et al. Sensitive and specific
method for the simultaneous determination of natural and synthetic cat-
echolamines and 3,4-dihydroxyphenylglycol in microdialysis samples.
J Chromatogr B Biomed Sci Appl. 1999;730:213–219.
17. Haitsma DB, Bac D, Raja N, et al. Minimal impairment of myocardial
blood flow responses to exercise in the remodeled left ventricle early after
myocardial infarction, despite significant hemodynamic and neuro-
humoral alterations. Cardiovasc Res. 2001;52:417–428.
18. Abrahamsen J, Nedergaard OA. Presynaptic action of adrenaline on
adrenoceptors modulating stimulation-evoked 3H-noradrenaline release
from rabbit isolated aorta. Naunyn Schmiedebergs Arch Pharmacol.
1989;339:281–287.
19. Goldstein DS, Golczynska A, Stuhlmuller J, et al. A test of the “epineph-
rine hypothesis” in humans. Hypertension. 1999;33:36–43.
20. Sadeghi HM, Eikenburg DC. Chronic epinephrine treatment fails to alter
prejunctional adrenoceptor modulation of sympathetic neurotransmission
in the rat mesentery. J Pharmacol Exp Ther. 1992;261:924–930.
21. Nezu M, Miura Y, Adachi M, et al. The effects of epinephrine on
norepinephrine release in essential hypertension. Hypertension. 1985;7:
187–195.
22. Stein CM, Nelson R, He HB, et al. Norepinephrine release in the human
forearm: effects of epinephrine. Hypertension. 1997;30:1078–1084.
23. Verdouw PD, Sassen LMA, Duncker DJ, et al. Nicorandil-induced
changes in the distribution of cardiac output and coronary blood flow in
pigs. Naunyn Schmiedebergs Arch Pharmacol. 1987;336:352–358.
24. Kawada T, Yamazaki T, Akiyama T, et al. Local epinephrine release in
the rabbit myocardial interstitium in vivo. J Auton Nerv Syst. 2000;78:
94–98.
25. Kawai C, Yui Y, Hoshino T, et al. Myocardial catecholamines in hyper-
trophic and dilated (congestive) cardiomyopathy: a biopsy study. J Am
Coll Cardiol. 1983;2:834–840.
26. Halter JB, Kelley KO, Gould KL. Cardiac uptake and secretion of cate-
cholamines during adrenergic stimulation in vivo. Am J Physiol. 1982;
243:E52–E58.
27. Eisenhofer G, Esler MD, Cox HS, et al. Differences in the neuronal
removal of circulating epinephrine and norepinephrine. J Clin Endocrinol
Metab. 1990;70:1710–1720.
28. Eisenhofer G, Smolich JJ, Esler MD. Disposition of endogenous
adrenaline compared to noradrenaline released by cardiac sympathetic
nerves in the anaesthetized dog. Naunyn Schmiedebergs Arch Pharmacol.
1992;345:160–171.
Lameris et al Epinephrine in the Heart 865
